Pull to refresh
Logo
Molecular Designs wins first FDA clearance for a flu and RSV test

Molecular Designs wins first FDA clearance for a flu and RSV test

New Capabilities

The Birmingham assay maker's SimplicityDx panel is cleared for high-complexity labs, but orders are not yet open

Overview

Updated 3 hours ago

Molecular Designs has sold molecular reagents labeled for research use only. On Nov. 13, the Food and Drug Administration cleared its first diagnostic: one run that detects and separates influenza A, influenza B and respiratory syncytial virus from a single anterior nasal swab.

The clearance, numbered K262789, covers prescription use in laboratories certified under the Clinical Laboratory Improvement Amendments to run high-complexity tests. The panel's pitch is workflow rather than a wider menu. A breakaway plate lets a lab run only the tests it needs for a given batch.

Why it matters

High-complexity labs get another cleared three-virus panel to stretch capacity in respiratory season, if Molecular Designs can start shipping.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

1
FDA-cleared assays for Molecular Designs
The SimplicityDx panel is the company's first cleared diagnostic.
3
Respiratory viruses detected in one run
Influenza A, influenza B and RSV, plus an internal control.
4
Viruses in the panel filed in October 2025
That earlier submission also covered SARS-CoV-2.
K262789
FDA 510(k) number
The identifier laboratories can check against FDA records.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

October 2025 November 2026

3 events Latest: 2 days ago
  1. FDA clears the SimplicityDx flu and RSV panel

    Latest Regulatory

    Clearance K262789 covers influenza A, influenza B and RSV in anterior nasal swabs for high-complexity laboratories.

  2. Company lists panel as available to order soon

    Commercial

    The product page invites laboratories to join a waitlist rather than place orders.

  3. Molecular Designs files for a four-virus respiratory panel

    Regulatory

    The 510(k) submission described a panel covering SARS-CoV-2, influenza A, influenza B and RSV with an internal control.

Scenarios

1

SimplicityDx orders open before spring 2027

Likely Resolves by Q1 2027

Discussed by: Molecular Designs product page and trade coverage

The clearance permits marketing, but the company's product page still says the panel is available to order soon and offers a waitlist. If manufacturing and distribution are ready, that label flips and labs can begin validation and purchasing ahead of the next respiratory season.

2

Molecular Designs wins a second clearance adding SARS-CoV-2

Possible Resolves by End of 2027

Discussed by: Medusa Path, which noted the clearance does not establish a pathway for additional assays

The company's October 2025 filing described a four-virus panel including SARS-CoV-2. A separate clearance covering that configuration would let it compete for combined COVID and respiratory testing, though the company has not said whether that filing remains under review.

3

Molecular Designs names its first U.S. laboratory customer

Possible Resolves by Q2 2027

Discussed by: Medusa Path's adoption analysis, which argues clearance alone does not settle laboratory uptake

Regulatory clearance opens procurement and validation but does not guarantee adoption. A named customer announcement would show the panel has cleared a laboratory's own validation and is being used for patient reporting rather than evaluation.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

October 2025

SimplicityDx Respiratory Panel submission (2025)

Molecular Designs filed a 510(k) for a panel detecting SARS-CoV-2 with two targets, influenza A, influenza B and RSV with two targets, plus an internal control. The company promoted a breakaway format to cut waste and manage inventory.

Then

The November 2026 clearance covers influenza A, influenza B and RSV. The announcement does not say what happened to the SARS-CoV-2 configuration.

Now

The company's first cleared diagnostic arrived with a narrower menu than the one it originally described.

Why this matters now

The clearance is a step in a product sequence, not a standalone event, and the gap between filing and clearance defines what the company can sell now.

Before November 2026

Molecular Designs' research-use-only respiratory line

Molecular Designs sold direct-PCR Covid, flu and RSV Simplicity Panel products labeled for research use only and not for diagnostic procedures. Such labeling keeps reagents outside FDA device review.

Then

The company had respiratory products in laboratories but no test cleared for patient reporting.

Now

The 510(k) moves one product line across that boundary; it does not convert the company's separate research-use-only products into diagnostics.

Why this matters now

Explains why a first clearance matters for a company that already sells respiratory tests and now wants diagnostic customers.

Sources

(5)